-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $35

Benzinga·09/25/2026 10:28:53
Listen to the news
Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $41 to $35.